ArticleMedicine2025
Identification and experimental validation of biomarkers associated with paraptosis in meningioma.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Crosstalk Between Autophagy and Paraptosis: A New Frontier in Cancer Therapy.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research suggests that programmed cell death may play a key role in meningioma, yet the mechanisms involving paraptosis-related genes (PRGs) remain unclear. This study aimed to identify biomarkers for meningioma that were associated with PRGs, providing new targets and strategies for therapeutic intervention. Meningioma-related datasets (GSE43290 and GSE77259) were retrieved from public databases. Initially, candidate genes were identified by overlapping PRGs with differentially expressed genes (tumor vs control). Biomarkers were then ascertained through protein-protein interaction (PPI) analysis and gene expression analysis. To further investigate the biological mechanisms of these biomarkers, functional enrichment, regulatory network, drug prediction, molecular docking, and reverse transcription quantitative polymerase chain reaction analyses were conducted. The design and implementation of this study strictly adhered to internationally recognized research standards and relevant regulations: Clinical procedures and sample collection complied with the Declaration of Helsinki, Chinese medical regulations, and the ethical review standards of the First Hospital of Lanzhou University. Data management followed GDPR requirements for anonymization and storage. The study identified ITPR3, MAPK1, and MAPK8 as biomarkers for meningioma. ITPR3 was found to be upregulated in tumor samples, while MAPK1 and MAPK8 exhibited significantly reduced expression in tumor samples. Meanwhile, reverse transcription quantitative polymerase chain reaction analysis confirmed these findings. Evidently, biomarkers were predominantly enriched in the "olfactory transduction" pathway. Regulatory network analysis predicted 130, 138, and 123 transcription factors targeting ITPR3, MAPK1, and MAPK8, respectively. Notably, SMAD3 was found to co-target all 3 biomarkers. Additionally, interactions involving MAPK1-"hsa-miR-130a-3p"-MIR17HG, MAPK8-"hsa-miR-32-5p"-NORAD, and ITPR3-"hsa-miR-506-3p"-MALAT1 were identified. Furthermore, drug prediction analysis suggested that tamoxifen could co-target these 3 biomarkers, with ITPR3 and tamoxifen exhibiting the strongest binding energy of -9.0 kcal/mol. ITPR3, MAPK1, and MAPK8 are biomarkers for meningioma, all targeted by SMAD3. Tamoxifen could treat meningioma by affecting paraptosis pathways, offering a promising basis for targeted therapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.